These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38432056)

  • 1. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
    Amblard F; LeCher JC; De R; Zhou S; Liu P; Goh SL; Tao S; Patel D; Downs-Bowen J; Zandi K; Zhang H; Chaudhry G; McBrayer T; Muczynski M; Al-Homoudi A; Engel J; Lan S; Sarafianos SG; Kovari LC; Schinazi RF
    Eur J Med Chem; 2024 Mar; 268():116263. PubMed ID: 38432056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics?
    Algar-Lizana S; Bonache MÁ; González-Muñiz R
    J Pept Sci; 2023 May; 29(5):e3467. PubMed ID: 36479966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
    Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites.
    Iketani S; Hong SJ; Sheng J; Bahari F; Culbertson B; Atanaki FF; Aditham AK; Kratz AF; Luck MI; Tian R; Goff SP; Montazeri H; Sabo Y; Ho DD; Chavez A
    Cell Host Microbe; 2022 Oct; 30(10):1354-1362.e6. PubMed ID: 36029764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
    Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19.
    Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD
    J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eupatin, a Flavonoid, Inhibits Coronavirus 3CL Protease and Replication.
    Park YI; Kim JH; Lee S; Lee IS; Park J
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors.
    Zhang R; Yan H; Zhou J; Yan G; Liu X; Shang C; Chen Y
    J Med Virol; 2024 Mar; 96(3):e29498. PubMed ID: 38436148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.
    Moon P; Zammit CM; Shao Q; Dovala D; Boike L; Henning NJ; Knapp M; Spradlin JN; Ward CC; Wolleb H; Fuller D; Blake G; Murphy JP; Wang F; Lu Y; Moquin SA; Tandeske L; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Toste FD; Nomura DK
    Chembiochem; 2023 Jun; 24(11):e202300116. PubMed ID: 37069799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.